UK markets close in 8 hours 25 minutes

Burning Rock Biotech Limited (BNR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.600.00 (0.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.60
Open7.63
Bid5.40 x 200
Ask9.76 x 200
Day's range7.59 - 8.16
52-week range5.72 - 29.20
Volume13,165
Avg. volume4,926
Market cap77.966M
Beta (5Y monthly)0.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

    GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:0

  • GlobeNewswire

    Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024

    GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS represe

  • GlobeNewswire

    Burning Rock Publishes 2023 Annual Report on Form 20-F

    GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website